Form 4 for ALLO Allogene Therapeutics, Inc.
Accepted 2022-03-25 00:00:00 ET · period of report 2022-03-23 · accession 0001214659-22-004371 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-25 | 2022-03-23 | ALLO | SCHMIDT ERIC THOMAS | CFO | A - Grant | $0.00 | +237.4K | 337.9K | +236% | $0 |
| D | 2022-03-25 | 2022-03-23 | ALLO | SCHMIDT ERIC THOMAS | CFO | A - Grant | $0.00 | +368.6K | 368.6K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-23 | A | A | 237,358 | $0.00 | 337,904 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-03-23 | A | A | 368,589 | $0.00 | 368,589 | D | $9.69 · — to 2032-03-23 | 368,589 Common Stock | (F1) 25% of the shares subject to the stock option shall vest on March 13, 2023, and the remaining shares shall vest in 36 equal monthly installments thereafter |